Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study

被引:7
作者
Liu, Zengjun [1 ]
Xu, Jing [1 ]
Liu, Mengyao [1 ]
Hu, Wenyu [1 ]
Xu, Ni [1 ]
Zhu, Dongyuan [1 ]
机构
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China
关键词
PHASE-II; OPEN-LABEL; MULTICENTER; SUNITINIB; PAZOPANIB;
D O I
10.1038/s41598-023-30412-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Angiogenesis inhibitors (AIs) and immune checkpoint inhibitors (ICIs) are new treatment options for advanced soft tissue sarcoma (STS) patients. This study evaluated the efficacy and safety of AIs plus ICIs in patients with advanced STS. A retrospective cohort study was performed on STS patients treated with AIs and ICIs at Shandong Cancer Hospital and Institute between August 2020 and December 2021. The primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and adverse events. Thirty-three patients were enrolled; 27 were evaluable for objective response. The ORR and DCR were 48.1% (95% CI 30.7-66.0%) and 85.2% (95% CI 67.5-94.1%). With a median follow-up of 7.6 months (range, 0.8-25.5), the median PFS for all 33 patients was 8.90 months (95% CI 5.98-11.82). The median OS was not reached. The most common treatment-related adverse events (TRAEs) of any grade were hypertension (50.0%), ECG T-wave abnormality (30.0%), hypothyroidism (26.7%), elevated alanine aminotransferase or aspartate aminotransferase (23.3%), elevated thyroid-stimulating hormone (23.3%), and fatigue (16.7%). The most common grade 3-4 TRAE was hypertension (27.3%). Three serious TRAEs (two myocarditis and one rapid atrial fibrillation) were recorded. This study suggests that adding AIs to ICIs is beneficial in STS.
引用
收藏
页数:8
相关论文
共 23 条
[1]   Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study [J].
Ben-Ami, Eytan ;
Barysauskas, Constance M. ;
Solomon, Sarah ;
Tahlil, Kadija ;
Malley, Rita ;
Hohos, Melissa ;
Polson, Kathleen ;
Loucks, Margaret ;
Severgnini, Mariano ;
Patel, Tara ;
Cunningham, Amy ;
Rodig, Scott J. ;
Hodi, F. Stephen ;
Morgan, Jeffrey A. ;
Merriam, Priscilla ;
Wagner, Andrew J. ;
Shapiro, Geoffrey I. ;
George, Suzanne .
CANCER, 2017, 123 (17) :3285-3290
[2]   Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072 [J].
Benson, C. ;
Ray-Coquard, I. ;
Sleijfer, S. ;
Litiere, S. ;
Blay, J. -Y. ;
Le Cesne, A. ;
Papai, Z. ;
Judson, I. ;
Schoffski, P. ;
Chawla, S. ;
Gil, T. ;
Piperno-Neumann, S. ;
Marreaud, S. ;
Dewji, M. R. ;
van der Graaf, W. T. A. .
GYNECOLOGIC ONCOLOGY, 2016, 142 (01) :89-94
[3]   Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma [J].
Chi, Yihebali ;
Fang, Zhiwei ;
Hong, Xiaonan ;
Yao, Yang ;
Sun, Ping ;
Wang, Guowen ;
Du, Feng ;
Sun, Yongkun ;
Wu, Qiong ;
Qu, Guofan ;
Wang, Shusen ;
Song, Jianmin ;
Yu, Jianchun ;
Lu, Yongkui ;
Zhu, Xia ;
Niu, Xiaohui ;
He, Zhiyong ;
Wang, Jinwan ;
Yu, Hao ;
Cai, Jianqiang .
CLINICAL CANCER RESEARCH, 2018, 24 (21) :5233-5238
[4]   Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials [J].
D'Angelo, Sandra P. ;
Mahoney, Michelle R. ;
Van Tine, Brian A. ;
Atkins, James ;
Milhem, Mohammed M. ;
Jahagirdar, Balkrishna N. ;
Antonescu, Cristina R. ;
Horvath, Elise ;
Tap, William D. ;
Schwartz, Gary K. ;
Streicher, Howard .
LANCET ONCOLOGY, 2018, 19 (03) :416-426
[5]   Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma [J].
Davis, Lara E. ;
Bolejack, Vanessa ;
Ryan, Christopher W. ;
Ganjoo, Kristen N. ;
Loggers, Elizabeth T. ;
Chawla, Sant ;
Agulnik, Mark ;
Livingston, Michael B. ;
Reed, Damon ;
Keedy, Vicky ;
Rushing, Daniel ;
Okuno, Scott ;
Reinke, Denise K. ;
Riedel, Richard F. ;
Attia, Steven ;
Mascarenhas, Leo ;
Maki, Robert G. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (16) :1424-+
[6]   Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas [J].
George, Suzanne ;
Merriam, Priscilla ;
Maki, Robert G. ;
Van den Abbeele, Annick D. ;
Yap, Jeffrey T. ;
Akhurst, Timothy ;
Harmon, David C. ;
Bhuchar, Gauri ;
O'Mara, Margaret M. ;
D'Adamo, David R. ;
Morgan, Jeffrey ;
Schwartz, Gary K. ;
Wagner, Andrew J. ;
Butrynski, James E. ;
Demetri, George D. ;
Keohan, Mary L. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3154-3160
[7]   Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway [J].
Kato, Yu ;
Tabata, Kimiyo ;
Kimura, Takayuki ;
Yachie-Kinoshita, Ayako ;
Ozawa, Yoichi ;
Yamada, Kazuhiko ;
Ito, Junichi ;
Tachino, Sho ;
Hori, Yusaku ;
Matsuki, Masahiro ;
Matsuoka, Yukiko ;
Ghosh, Samik ;
Kitano, Hiroaki ;
Nomoto, Kenichi ;
Matsui, Junji ;
Funahashi, Yasuhiro .
PLOS ONE, 2019, 14 (02)
[8]   Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab [J].
Keung, Emily Z. ;
Burgess, Melissa ;
Salazar, Ruth ;
Parra, Edwin R. ;
Rodrigues-Canales, Jaime ;
Bolejack, Vanessa ;
Van Tine, Brian A. ;
Schuetze, Scott M. ;
Attia, Steven ;
Riedel, Richard F. ;
Hu, James ;
Okuno, Scott H. ;
Priebat, Dennis A. ;
Movva, Sujana ;
Davis, Lara E. ;
Reed, Damon R. ;
Reuben, Alexandre ;
Roland, Christina L. ;
Reinke, Denise ;
Lazar, Alexander J. ;
Wang, Wei-Lien ;
Wargo, Jennifer A. ;
Tawbi, Hussein A. .
CLINICAL CANCER RESEARCH, 2020, 26 (06) :1258-1266
[9]   Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis [J].
Kollar, A. ;
Jones, R. L. ;
Stacchiotti, S. ;
Gelderblom, H. ;
Guida, M. ;
Grignani, G. ;
Steeghs, N. ;
Safwat, A. ;
Katz, D. ;
Duffaud, F. ;
Sleijfer, S. ;
van der Graaf, W. T. ;
Touati, N. ;
Litiere, S. ;
Marreaud, S. ;
Gronchi, A. ;
Kasper, B. .
ACTA ONCOLOGICA, 2017, 56 (01) :88-92
[10]   Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity [J].
Lee, Won Suk ;
Yang, Hannah ;
Chon, Hong Jae ;
Kim, Chan .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2020, 52 (09) :1475-1485